|
 |
San Antonio Roundup
Source: (cancerfacts.com)
Thursday, December 17, 2009
First of four summaries of studies presented at the San Antonio Breast Cancer conference Dec. 9-13
SAN ANTONIO – Dec. 17, 2009 – A number of studies showing advances in the treatment of breast cancer were highlighted at a press conference held in advance of the San Antonio Breast Cancer Symposium Dec. 9-13. Moderated by Dr. Edith Perez, director of the Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., the following is one of four highlighted during the press conference, which were presented during sessions at the symposium.
Targeted therapies in tandem improve survival
Two targeted therapies - lapatinib plus trastuzumab - are better than one in the fight against HER2-positive metastatic breast cancer, according to study results presented at the CTRC-AACR San Antonio Breast Cancer Symposium.
"These two targeted therapies against HER2, sort of a 'one-two punch,' conveyed a more than four-month significant improvement in survival when compared to lapatinib alone," said Dr. Kimberly L. Blackwell, associate professor of medicine and director of the Clinical Trials Program in Breast Cancer at Duke University Medical Center.
What makes these results stand out from previous studies, according to Blackwell, is that this study demonstrated an improvement in survival without the incorporation of endocrine therapy or chemotherapy.
"We demonstrated the effectiveness of combined targeted therapy; no other study has examined this combination in a phase III, randomized design," she said.
The researchers randomized 296 women with metastatic breast cancer to receive lapatinib 1,500 mg once a day or lapatinib 1,000 mg once a day in combination with trastuzumab 2 mg/kg every week. The women's tumors had progressed on a number of trastuzumab-chemotherapy combination treatments, and they were faced with limited treatment options prior to study entry.
Lapatinib, marketed as Tykerb®, is an orally active small molecule inhibitor against HER2 and epidermal growth factor receptor for use against solid tumors, and for combination therapy for metastatic breast cancer patients. Trastuzumab, marketed as Herceptin®, is a monoclonal antibody that binds selectively to the HER2 protein, and has demonstrated benefits when combined with chemotherapy in early stage and metastatic breast cancer patients.
Overall survival significantly improved among the patients who used combination therapy, compared with those who were treated with the lapatinib monotherapy, they found. Even after adjusting for prognostic factors, the survival benefit was maintained.
Further, Blackwell and colleagues noted a trend toward a 25 percent reduction in risk of death.
The same combination of lapatinib and trastuzumab from this study is now being compared to either drug alone in the prevention of breast cancer recurrence in patients faced with HER2-positive, early stage breast cancer.
"In the treatment of HER2-positive breast cancer, we have highly effective treatments and when we combine them, we can make a significant difference in survival," she said. "This represents a step forward toward a day when we don't have to give chemotherapy for breast cancer at all."
SOURCE: adapted from press materials provided by the American Association of Cancer Research
Copyright © 2002, 2003, 2004, 2005, 2006, 2007, 2008 NexCura, Inc. All rights reserved. Republication or redistribution of cancerfacts.com content, including by framing or similar means, is expressly prohibited without the prior written consent of NexCura. NexCura® is a registered trademark and cancerfacts.com™ is a trademark of NexCura, Inc. or its affiliates. Copyright © 2003, 2004, 2005 2006, 2007, 2008, 2009. All rights reserved. This information is for educational purposes only.
|
|
|
|
|
|
